Abstract
The mitoribosome synthesizes 13 protein subunits of the oxidative phosphorylation system encoded by the mitochondrial genome. The mitoribosome is composed of 12S rRNA, 16S rRNA and 82 mitoribosomal proteins encoded by nuclear genes. To date, variants in 12 genes encoding mitoribosomal proteins are associated with rare monogenic disorders, and frequently show combined oxidative phosphorylation deficiency. Here, we describe five unrelated individuals with biallelic variants in the DAP3 nuclear gene encoding mitoribosomal small subunit 29 (MRPS29), with variable clinical presentations ranging from Perrault syndrome (sensorineural hearing loss and ovarian insufficiency) to an early childhood neurometabolic phenotype. Assessment of respiratory chain function and proteomic profiling of fibroblasts from affected individuals demonstrated reduced MRPS29 protein levels, and consequently decreased levels of additional protein components of the mitoribosomal small subunit, associated with a combined complex I and IV deficiency. Lentiviral transduction of fibroblasts from affected individuals with wild-type DAP3 cDNA increased DAP3 mRNA expression, and partially rescued protein levels of MRPS7, MRPS9 and complex I and IV subunits, demonstrating the pathogenicity of the DAP3 variants. Protein modelling suggested that DAP3 disease-associated missense variants can impact ADP binding, and in vitro assays demonstrated DAP3 variants can consequently reduce both intrinsic and extrinsic apoptotic sensitivity, DAP3 thermal stability and DAP3 GTPase activity. Our study presents genetic and functional evidence that biallelic variants in DAP3 result in a multisystem disorder of combined oxidative phosphorylation deficiency with pleiotropic presentations, consistent with mitochondrial dysfunction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Medical Research Council (MR/W019027/1 ROK, RWT and WGN), Action on Hearing Loss (S35 Newman); Royal National Institute for the Deaf and Masonic Charitable Foundation (S60_Newman); Action Medical Research (GN2494); NIHR Manchester Biomedical Research Centre ((IS-BRC-1215-20007 and NIHR203308); Infertility Research Trust; Wellcome Trust ISSF pump-prime award [097820/Z/11/B]; the Wellcome Trust Centre for Mitochondrial Research (203105/Z/16/Z to RWT); the UK NHS Highly Specialised Rare Mitochondrial Disorders of Adults and Children Service (RWT); and The Lily Foundation (RWT) through PhD studentship funding to RICG; DBT/Wellcome Trust India Alliance for the study, Centre for Rare Disease Diagnosis, Research and Training (IA/CRC/20/1/600002); in part by the Intramural Research Program of the NIDCD at the NIH (DC000039 to TBF). The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between Wellcome and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051]. The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was granted by the UK National Health Service Ethics Committee (16/WA/0017) and the University of Manchester.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵Δ Senior author.
Data Availability
All data produced in the present work are contained in the manuscript and supplementary information.
